查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1842069

美國醫療CDMO（受託製造廠商）市場：市場規模、佔有率和趨勢分析（按類型、產品、服務、工作流程、治療領域和最終用途分類），按細分市場預測（2025-2033年）

U.S. Healthcare Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Type, By Product, By Service, By Workflow, By Therapeutic Area, By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

美國醫療CDMO市場概覽

美國醫療 CDMO（受託製造廠商）市場預計在 2024 年達到 653 億美元，預計到 2033 年將達到 1,442 億美元，2025 年至 2033 年的複合年成長率為 9.41%。

由於對包括生技藥品、生物相似藥以及細胞和基因療法在內的先進療法的需求不斷成長，美國醫療保健CDMO市場正在快速擴張。此外，製藥公司日益關注腫瘤學、罕見疾病和免疫學領域的研發，這需要高度專業化的生產製造技術。

CDMO（合約研發生產機構）提供許多公司內部缺乏的關鍵基礎設施、擴充性和技術能力。強勁的研發管線、生技藥品專利到期以及個人化醫療的加速發展進一步推動了CDMO的成長。這使得CDMO成為加速複雜治療藥物研發速度、降低成本並實現合規生產的重要合作夥伴。製藥和生物技術公司與CDMO合作，以降低營運成本並加速產品開發。此外，CDMO服務的興起也得益於以下事實：建立內部生產設施需要大量的資金投入、員工培訓和合規性審查，這可能會減緩創新。

此外，CDMO 為製藥和醫療設備公司提供先進技術、大規模生產設施和靈活生產模式的即時獲取途徑。這種夥伴關係最大限度地降低了財務風險，使製藥公司能夠專注於核心研發，同時利用 CDMO 進行臨床和商業化生產。在競爭激烈的市場中，速度至關重要，CDMO 提供了一條敏捷且經濟高效的途徑，能夠更快地將藥物推向市場，從而確保競爭優勢和盈利。

美國醫療產業在FDA和全球法規的嚴格框架下運作，要求嚴格遵守GMP標準、驗證和文件記錄。此外，滿足這些合規要求對製藥公司而言可能耗費大量資源。然而，CDMO擁有深厚的監管專業知識、完善的品質系統以及豐富的全球申請管理經驗，可以降低延誤和違規的風險。 CDMO持續滿足不斷變化的監管標準的能力有助於建立信任和信心。此外，CDMO正在投資數位化、自動化和數據主導的合規系統，並加強監管。這些監管方面的專業知識使CDMO成為重要的策略合作夥伴，使製藥公司能夠專注於創新，同時確保產品品質和病患安全。

目錄

第1章 分析方法和範圍

第2章執行摘要

第3章：美國醫療CDMO市場：促進因素、趨勢與範圍

  • 市場關聯性展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 技術格局
  • 定價模式分析
  • 關稅影響分析
  • 價值鏈分析
    • 供應趨勢
    • 需求趨勢
  • 市場分析工具
    • 波特五力分析
    • PESTEL分析與SWOT分析

第4章：美國醫療CDMO市場：按類型分類的估算與趨勢分析

  • 美國醫療CDMO市場：按類型分類的概覽
  • 美國醫療CDMO市場：按類型分類的變化分析
  • 按類型（2021-2033 年）
  • 低分子
    • 品牌
    • 非專利的
  • 聚合物
    • 生技藥品
    • 生物相似藥
  • 醫療設備
    • 診斷
    • 治療

第5章：美國醫療CDMO市場：按產品分類的估算與趨勢分析

  • 美國醫療CDMO市場：產品概覽
  • 美國醫療CDMO市場：按產品分類的變化分析
  • 依產品分類（2021-2033 年）
  • 製藥
    • API
    • 製藥
  • 醫療設備
    • 一級
    • II 類
    • III 類

第6章：美國醫療CDMO市場：按服務類型分類的估算與趨勢分析

  • 美國醫療保健CDMO市場：按服務分類的儀表板
  • 美國醫療保健CDMO市場：按服務分類的變化分析
  • 依服務年資（2021-2033）
  • 合約開發
    • 預配方和配方開發服務
    • 製程開發與最佳化
    • 分析測試和方法檢驗
    • 規模化和技術轉移
  • 契約製造
    • 原料藥（API）生產
    • 成品藥生產
    • 醫療設備和複雜產品
  • 包裝和標籤
  • 監管事務
  • 其他

第7章：美國醫療CDMO市場：依工作流程分類的估算與趨勢分析

  • 美國醫療CDMO市場：工作流程儀錶板
  • 美國醫療CDMO市場：按工作流程分類的差異分析
  • 按工作流程（2021-2033）
  • 臨床
  • 上市

第8章：美國醫療CDMO市場：按治療領域分類的估算與趨勢分析

  • 美國醫療保健CDMO市場：治療領域概覽
  • 美國醫療保健CDMO市場：按治療領域分類的趨勢分析
  • 依治療領域分類（2021-2033 年）
  • 瘤
  • 感染疾病
  • 神經系統疾病
  • 心血管疾病
  • 代謝紊亂
  • 自體免疫疾病
  • 呼吸系統疾病
  • 眼科
  • 胃腸道疾病
  • 整形外科疾病
  • 牙科疾病
  • 其他

第9章：美國醫療CDMO市場：依最終用途分類的估算與趨勢分析

  • 美國醫療CDMO市場：按最終用途分類的概覽
  • 美國醫療CDMO市場：按最終用途分類的變化分析
  • 依最終用途分類（2021-2033 年）
  • 製藥和生物技術公司
  • 醫療設備公司
  • 其他

第10章 競爭格局

  • 主要參與者的分類
    • 市場領導
    • 新興企業
  • 市佔率/估值分析（熱力圖分析），2024 年
  • 公司簡介
    • Catalent Inc.
    • Lonza
    • Recipharm AB
    • Siegfried Holding AG
    • Thermo Fisher Scientific, Inc.
    • Labcorp Drug Development
    • Jabil Inc
    • Syngene International Limited
    • IQVIA Inc.
    • Almac Group
    • Ajinomoto Bio-Pharma
    • Adare Pharma Solutions
    • Alcami Corporation
    • Vetter Pharma International
Product Code: GVR-4-68040-749-6

U.S. Healthcare Contract Development And Manufacturing Organization Market Summary

The U.S. healthcare contract development and manufacturing organization market size was estimated at USD 65.3 billion in 2024 and is projected to reach USD 144.2 billion by 2033, growing at a CAGR of 9.41% from 2025 to 2033. The U.S. healthcare CDMO market is expanding rapidly, driven by rising demand for biologics, biosimilars, and advanced therapies, including cell and gene therapies. Besides, pharmaceutical companies are increasingly focused on R&D in oncology, rare diseases, and immunology, creating the need for highly specialized manufacturing expertise.

CDMOs provide critical infrastructure, scalability, and technical capabilities that many firms lack internally. Growth is further reinforced by strong pipeline activity, patent expirations of biologics, and the acceleration of personalized medicine. This has led CDMOs to become essential partners in enabling faster development timelines, cost efficiency, and compliant production of complex therapies. Pharmaceutical and biotech companies are partnering with CDMOs to reduce operational costs and accelerate product development. Besides, among pharmaceutical companies, establishing in-house facilities requires substantial capital investment, workforce training, and regulatory compliance, which may slow innovation, which has further led to the rise of CDMO services.

In addition, CDMOs offer pharmaceutical and medical device companies' immediate access to advanced technologies, large-scale facilities, and flexible production models. This partnership supports minimizing the financial risks and allows pharma companies to focus on core R&D while leveraging CDMOs for clinical and commercial manufacturing. In a highly competitive market where speed is critical, CDMOs offer an agile and cost-efficient pathway to bring drugs to market faster, ensuring competitive advantage and profitability.

The U.S. healthcare industry operates under stringent FDA and global regulatory frameworks, requiring strict adherence to GMP standards, validation, and documentation. Besides, navigating these compliance requirements can be highly resource-intensive for pharma companies. CDMOs, however, possess deep regulatory expertise, established quality systems, and experience managing global submissions, reducing the risk of delays and non-compliance. Their ability to consistently meet evolving regulatory standards enhances trust and reliability. In addition, CDMOs are investing in digitalization, automation, and data-driven compliance systems to strengthen oversight. This regulatory know-how makes CDMOs indispensable strategic partners, enabling pharma companies to focus on innovation while ensuring product quality and patient safety.

U.S. Healthcare Contract Development And Manufacturing Organization Market Report Segmentation

This report forecasts revenue growth at and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. healthcare contract development and manufacturing organization market report based on type, product, service, workflow, therapeutic area, and end use:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Small Molecule
  • Branded
  • Generic
  • Large Molecule
  • Biologics
  • Biosimilar
  • Medical Device
  • Diagnostics
  • Therapeutics
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical
  • API
    • Traditional API
    • HP-API
    • Biologics
    • Others
  • Drug Product
    • Oral topical dose
    • Semi-solid dose
    • Liquid dose
    • Others
  • Medical Devices
  • Class I
  • Class II
  • Class III
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Contract Development
  • Pre-formulation & Formulation Development Service
  • Process Development & Optimization
  • Analytical Testing & Method Validation
  • Scale-up & Tech Transfer
  • Contract Manufacturing
  • API Manufacturing
  • Finished drug products Manufacturing
  • Medical Devices & Combination Products
  • Packaging and labelling
  • Regulatory Affairs
  • Others
  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical
  • Commercial
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Infectious Diseases
  • Neurological Disorders
  • Cardiovascular Disease
  • Metabolic Disorders
  • Autoimmune Diseases
  • Respiratory Diseases
  • Ophthalmology
  • Gastrointestinal Disorders
  • Orthopedic Diseases
  • Dental Diseases
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biotechnology Companies
  • Medical Device Companies
  • Others

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Product
    • 1.2.3. Service
    • 1.2.4. Workflow
    • 1.2.5. Therapeutic Area
    • 1.2.6. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Top-Down Analysis
    • 1.7.3. Bottom-Up Approach
    • 1.7.4. Multivariate Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Healthcare Contract Development and Manufacturing Organization Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Tariff Impact Analysis
  • 3.6. Value Chain Analysis
    • 3.6.1. Supply Trends
    • 3.6.2. Demand Trends
  • 3.7. Market Analysis Tools
    • 3.7.1. Porter's Five Force Analysis
    • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Healthcare Contract Development and Manufacturing Organization Market: Type Estimates & Trend Analysis

  • 4.1. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Type: Segment Dashboard
  • 4.2. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Type: Movement Analysis
  • 4.3. U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
  • 4.4. Small Molecule
    • 4.4.1. Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Branded
      • 4.4.2.1. Branded Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Generic
      • 4.4.3.1. Generic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Large Molecule
    • 4.5.1. Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Biologics
      • 4.5.2.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Biosimilar
      • 4.5.3.1. Biosimilar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Medical Device
    • 4.6.1. Medical Device Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.2. Diagnostics
      • 4.6.2.1. Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.3. Therapeutics
      • 4.6.3.1. Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Healthcare Contract Development and Manufacturing Organization Market: Product Estimates & Trend Analysis

  • 5.1. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Product: Segment Dashboard
  • 5.2. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Product: Movement Analysis
  • 5.3. U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
  • 5.4. Pharmaceutical
    • 5.4.1. Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. API
      • 5.4.2.1. API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.2. Traditional API
        • 5.4.2.2.1. Traditional API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.3. HP-API
        • 5.4.2.3.1. HP-API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.4. Biologics
        • 5.4.2.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.5. Others
        • 5.4.2.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. Drug Product
      • 5.4.3.1. Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.3.2. Oral Topical Dose
        • 5.4.3.2.1. Oral Topical Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.3.3. Semi-Solid Dose
        • 5.4.3.3.1. Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.3.4. Liquid Dose
        • 5.4.3.4.1. Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.3.5. Others
        • 5.4.3.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Medical Devices
    • 5.5.1. Medical Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.2. Class I
      • 5.5.2.1. Class I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.3. Class II
      • 5.5.3.1. Class II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.4. Class III
      • 5.5.4.1. Class III Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Healthcare Contract Development and Manufacturing Organization Market: Service Estimates & Trend Analysis

  • 6.1. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Service: Segment Dashboard
  • 6.2. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Service: Movement Analysis
  • 6.3. U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
  • 6.4. Contract Development
    • 6.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Preformulation & Formulation Development Service
      • 6.4.2.1. Preformulation & Formulation Development Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Process Development & Optimization
      • 6.4.3.1. Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Analytical Testing & Method Validation
      • 6.4.4.1. Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.5. Scale-up & Tech Transfer
      • 6.4.5.1. Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Contract Manufacturing
    • 6.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. API Manufacturing
      • 6.5.2.1. API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Finished drug products Manufacturing
      • 6.5.3.1. Finished drug products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. Medical Devices & Combination Products
      • 6.5.4.1. Medical Devices & Combination Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Packaging and Labelling
    • 6.6.1. Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Regulatory Affairs
    • 6.7.1. Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Healthcare Contract Development and Manufacturing Organization Market: Workflow Estimates & Trend Analysis

  • 7.1. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Workflow: Segment Dashboard
  • 7.2. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Workflow: Movement Analysis
  • 7.3. U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
  • 7.4. Clinical
    • 7.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Commercial
    • 7.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Healthcare Contract Development and Manufacturing Organization Market: Therapeutic Area Estimates & Trend Analysis

  • 8.1. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Therapeutic Area: Segment Dashboard
  • 8.2. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Therapeutic Area: Movement Analysis
  • 8.3. U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
  • 8.4. Oncology
    • 8.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Infectious Diseases
    • 8.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Neurological Disorders
    • 8.6.1. Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Cardiovascular Disease
    • 8.7.1. Cardiovascular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Metabolic Disorders
    • 8.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9. Autoimmune Diseases
    • 8.9.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.10. Respiratory Diseases
    • 8.10.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.11. Ophthalmology
    • 8.11.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.12. Gastrointestinal Disorders
    • 8.12.1. Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.13. Orthopedic Diseases
    • 8.13.1. Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.14. Dental Diseases
    • 8.14.1. Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.15. Others
    • 8.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. U.S. Healthcare Contract Development and Manufacturing Organization Market: End Use Estimates & Trend Analysis

  • 9.1. U.S. Healthcare Contract Development and Manufacturing Organization Market, By End Use: Segment Dashboard
  • 9.2. U.S. Healthcare Contract Development and Manufacturing Organization Market, By End Use: Movement Analysis
  • 9.3. U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
  • 9.4. Pharmaceutical & Biotechnology Companies
    • 9.4.1. Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Medical Device Companies
    • 9.5.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Others
    • 9.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Key Participant Categorization
    • 10.1.1. Market Leaders
    • 10.1.2. Emerging Players
  • 10.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
  • 10.3. Company Profiles
    • 10.3.1. Catalent Inc.
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Service Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. Lonza
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Service Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. Recipharm AB
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Service Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. Siegfried Holding AG
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Service Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. Thermo Fisher Scientific, Inc.
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Service Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Labcorp Drug Development
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Service Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. Jabil Inc
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Service Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Syngene International Limited
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Service Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. IQVIA Inc.
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Service Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Almac Group
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Service Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. Ajinomoto Bio-Pharma
      • 10.3.11.1. Company Overview
      • 10.3.11.2. Financial Performance
      • 10.3.11.3. Service Benchmarking
      • 10.3.11.4. Strategic Initiatives
    • 10.3.12. Adare Pharma Solutions
      • 10.3.12.1. Company Overview
      • 10.3.12.2. Financial Performance
      • 10.3.12.3. Service Benchmarking
      • 10.3.12.4. Strategic Initiatives
    • 10.3.13. Alcami Corporation
      • 10.3.13.1. Company Overview
      • 10.3.13.2. Financial Performance
      • 10.3.13.3. Service Benchmarking
      • 10.3.13.4. Strategic Initiatives
    • 10.3.14. Vetter Pharma International
      • 10.3.14.1. Company Overview
      • 10.3.14.2. Financial Performance
      • 10.3.14.3. Service Benchmarking
      • 10.3.14.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 4 U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 5 U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 6 U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 7 U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 8 U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 U.S. Healthcare Contract Development and Manufacturing Organization Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. Healthcare Contract Development and Manufacturing Organization Market: Type outlook and key takeaways
  • Fig. 20 U.S. Healthcare Contract Development and Manufacturing Organization Market: Type movement analysis
  • Fig. 21 Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Branded Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Generic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Biosimilar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Medical Device Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. Healthcare Contract Development and Manufacturing Organization Market: Product outlook and key takeaways
  • Fig. 31 U.S. Healthcare Contract Development and Manufacturing Organization Market: Product movement analysis
  • Fig. 32 Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Traditional API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 HP-API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Oral Topical Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Medical Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Class I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Class II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Class III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 U.S. Healthcare Contract Development and Manufacturing Organization Market: Service outlook and key takeaways
  • Fig. 48 U.S. Healthcare Contract Development and Manufacturing Organization Market: Service movement analysis
  • Fig. 49 Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Preformulation & Formulation Development Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Finished drug products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Medical Devices & Combination Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 U.S. Healthcare Contract Development and Manufacturing Organization Market: Workflow outlook and key takeaways
  • Fig. 62 U.S. Healthcare Contract Development and Manufacturing Organization Market: Workflow movement analysis
  • Fig. 63 Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 U.S. Healthcare Contract Development and Manufacturing Organization Market: Therapeutic Area outlook and key takeaways
  • Fig. 66 U.S. Healthcare Contract Development and Manufacturing Organization Market: Therapeutic Area movement analysis
  • Fig. 67 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 U.S. Healthcare Contract Development and Manufacturing Organization Market: End Use outlook and key takeaways
  • Fig. 80 U.S. Healthcare Contract Development and Manufacturing Organization Market: End Use movement analysis
  • Fig. 81 Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key company categorization
  • Fig. 85 Service heat map analysis
  • Fig. 86 Strategic framework